Rapid Testing Cuts Time to Antibiotics for Pneumonia
A clinical trial found that rapid molecular pathogen testing significantly reduces the time required to provide appropriate antibiotic treatment for pneumonia patients. Patients receiving the rapid test received targeted therapy in 7 hours compared to 72 hours for those in the standard care group.
Why it matters
Faster diagnostic testing can drastically improve outcomes for critically ill patients and help combat antibiotic resistance.
Rapid molecular pathogen testing could substantially accelerate appropriate antibiotic treatment for critically ill patients with suspected pneumonia, according to findings from the IRISPAT-1 randomised controlled feasibility trial.
The article reports on medical trial results in a neutral, evidence-based manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in